Consistent with these findings, our study shows that cancer patients undergoing ICI therapy with low serum CEA levels have better OS, PFS, ORR, DCR, and pCR, indicating a more favorable response to immunotherapy. This evidence concerns the gene CEACAM5 and cancer.